Original language | English (US) |
---|---|
Pages (from-to) | 712-714 |
Number of pages | 3 |
Journal | Journal of the American College of Cardiology |
Volume | 74 |
Issue number | 5 |
DOIs | |
State | Published - Aug 6 2019 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American College of Cardiology, Vol. 74, No. 5, 06.08.2019, p. 712-714.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines
AU - Virani, Salim S.
AU - Akeroyd, Julia M.
AU - Smith, Sidney C.
AU - Al-Mallah, Mouaz
AU - Maddox, Thomas M.
AU - Morris, Pamela B.
AU - Petersen, Laura A.
AU - Ballantyne, Christie M.
AU - Grundy, Scott M.
AU - Stone, Neil J.
N1 - Funding Information: Please note: This work was supported by a Department of Veterans Affairs Health Services Research & Development (HSR&D) Service Investigator Initiated Grant (IIR 16-072), American Heart Association Beginning Grant-in-Aid (14BGIA20460366), and the Houston VA HSR&D Center for Innovations grant (grant CIN13-413). Dr. Maddox is supported by the National Institutions of Health/NCATS (1U24TR002306-01: A National Center for Digital Health Informatics Innovation). The opinions expressed reflect those of the authors and are not necessarily those of the Department of Veterans Affairs, the U.S. Government, or Baylor College of Medicine. Dr. Virani has received honorarium from the American College of Cardiology as the Associate Editor for Innovations. Dr. Maddox has been consultant for Creative Educational Concepts; and has received honoraria from Brown University, Washington State Clinical Outcomes Assessment Program (COAP), Virginia Mason, University of Utah, New York Presbyterian, Westchester Medical Center, Sentara Heart Hospital, and the Henry Ford Health System. Dr. Morris has been a member of the Advisory Board and a consultant for Amgen, Sanofi, and Regeneron. Dr. Ballantyne has served as a consultant for Abbott Diagnostics, Akcea, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Denka Seiken, Esperion, Intercept, Janssen, Matinas BioPharma Inc., Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, and Sanofi-Synthelabo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2019/8/6
Y1 - 2019/8/6
UR - http://www.scopus.com/inward/record.url?scp=85069568245&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069568245&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2019.05.051
DO - 10.1016/j.jacc.2019.05.051
M3 - Letter
C2 - 31370962
AN - SCOPUS:85069568245
SN - 0735-1097
VL - 74
SP - 712
EP - 714
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 5
ER -